Full Press Release Details
NOTICE OF CHANGE IN FISCAL YEAR END
Section 4.8 of National Instrument 51-102
TO: Autorit des march s financiers
Alberta Securities Commission
British Columbia Securities Commission
Manitoba Securities Commission
Ontario Securities Commission
This Notice is provided pursuant to the requirements of Part 4.8 of National Instrument 51 102 - Continuous Disclosure Obligations.
Acasti Pharma Inc. (the "Corporation") has decided to change its fiscal year end from February 28 to March 31.
This step is being taken to allow the Corporation to be better aligned with its industry comparables and standard quarters.
| Transition Year | Comparative Annual Financial Statements to Transition Year | New Financial Year | Comparative Annual Financial Statements to New Financial Year | Interim Periods for Transition Year | Comparative Interim Periods to Interim Periods in Transition Year | Interim Periods for New Financial Year | Comparative Interim Periods to Interim Periods in New Financial Year |
| 13 months ended March 31, 2017 | 12 months ended February 29, 2016 | March 31 | 13 months ended March 31, 2017 | 3 months ended May 31, 2016 | 3 months ended May 31, 2015 | 3 months ended June 30, 2017 | 3 months ended May 31, 2016 |
| 6 months ended August 31, 2016 | 6 months ended August 31, 2015 | 6 months ended September 30, 2017 | 6 months ended August 31, 2016 | ||||
| 9 months ended November 30, 2016 | 9 months ended November 30, 2015 | 9 months ended December 31, 2017 | 9 months Ended November 30, 2016 | ||||
| 13 months ended March 31, 2017 | 12 months ended February 29, 2016 |
Dated this 5th day of August 2016
/s/ Jean-Daniel B langer
Jean-Daniel B langer